NCT02473757

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Enrolling by Invitation
Not specifiedAges 18+Observational
National Cancer Institute (NCI)
~1,000 participants
Updated 2026-08-04 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To provide long term follow up of patients previously enrolled on treatment protocols in the NCI ETIB Branch.
Measured over 15 years
Lyphoma, B-Cell
Leukemia, B-cell
Multiple Myeloma
Hematologic Malignancies
1 sites across 1 states
Maryland1
  • James N Kochenderfer, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects who have received treatment on a CAR T-cell gene therapy protocol. Age \>= 18 years as children are generally excluded from CAR T-cell gene therapy studies.
  • To provide long term follow up of patients previously enrolled on treatment protocols in the NCI ETIB Branch.15 years

    List of long time adverse event frequency after Gene therapy drug